This website contains proprietary and confidential information. All data submitted to partners, associates or persons operating on behalf of, or with Apex Labs Ltd., is provided in reliance upon its consent not to use or disclose any information contained herein, except in the context of promotional and/or licensing activities officially sanctioned by Apex Labs Ltd. The recipient of this document agrees to inform its present and future employees and associates who view or have access to this document of its confidential nature.

The recipient agrees to instruct each employee or relevant persons that they must not disclose any information concerning this document to others except to the extent of such matters that are generally known to, and available for use by the general public. The recipient also agrees to not directly or indirectly duplicate or distribute any material contained herein without the expressed permission and written consent of Apex Labs Ltd.

Apex Labs Ltd. retains all title, ownership and intellectual property to the materials and contained herein, including all supporting documentation, files, and marketing material. All information in this document was provided for and approved by Apex Labs Ltd.

Intellectual Property

Genetic Registration & Rights

Apex Labs intellectual property development plan revolves around a quantified composition, new use, and invention claims approach. We combine these aspects together in order to bolster our claims to best suit strong and robust patent protection, specifically in organic molecular formulations.

There is an incredible opportunity for developing and securing intellectual property in the Psilocybin and Psychedelic space. Apex Labs is working hand in hand with our IP/patent counsel at Cooley LLP and BLG identifying the targets hosting the most opportunity to protect and to effectively capitalize on.


  • Reisman M. PTSD Treatment for Veterans: What’s Working, What’s New, and What’s Next. P T. 2016. Oct;41(10):623-634. PMID: 27757001; PMCID: PMC5047000.
  • Stefanovics EA, Potenza MN, Pietrzak RH. PTSD and obesity in U.S. military veterans: Prevalence, health burden, and suicidality. Psychiatry Res. 2020 Sep;291:113242. doi: 10.1016/j.psychres.2020.113242. Epub 2020 Jun 18. PMID: 32763532.
  • Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68:711–720. [PubMed] [Google Scholar]
  • Government of Canada, S. C. (2019, April 24). Canadian Armed Forces members and veteran mental health follow-up survey, 2018. The Daily – . Retrieved October 4, 2022, from https://www150.statcan.gc.ca/n1/daily-quotidien/190423/dq190423d-eng.htm
  • Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs. J Clin Psychiatry. 2008;69:959–965. [PubMed] [Google Scholar]
  • Depression: How effective are antidepressants? – NCBI bookshelf. (n.d.). Retrieved October 5, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK361016/
  • Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012 May;9(5-6):41-6. PMID: 22808448; PMCID: PMC3398686.
  • Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411.